News | February 01, 2023
Sun Pharma Q3 FY23 Gross Sales up 13.1%; Net profit up 5.2%
India formulation sales at Rs. 3,391.9 crore, up 7.1% over Q3 last year
India formulation sales at Rs. 3,391.9 crore, up 7.1% over Q3 last year
Spesolimab is a monoclonal antibody that inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for the treatment of generalized pustular psoriasis flares
Sun Pharma will receive from Cassiopea the exclusive right to develop and commercialize WINLEVI in Japan, Australia, New Zealand, Brazil, Mexico and Russia.
'Hello Skin' has been developed in collaboration with the IADVL (Indian Association of Dermatologists, Venereologists and Leprologists)
_256_384.jpg)
The deal will be financed by Rs 300 crore of internal accruals and Rs 350 crore of borrowings
The platform has seen an overall growth of 84% in the number of people seeking consultations for skin-related issues
Subscribe To Our Newsletter & Stay Updated
